Ranbaxy Laboratories

Sell Ranbaxy Labs below Rs 241.25: ICICIdirect.com

Posted by : MMB Messenger

ICICIdirect.com has recommended to sell Ranbaxy Laboratories below Rs 241.25 with a stoploss of Rs 242.25 and targets of Rs 239/235/lower.

Sell Ranbaxy Labs below Rs 241.25: ICICIdirect.com

Posted by : MMB Messenger

ICICIdirect.com has recommended to sell Ranbaxy Laboratories below Rs 241.25 with a stoploss of Rs 242.25 and targets of Rs 239/235/lower.

what is the future of ranbaxy?

Posted by : sanecouncel.

dear guest , do u know that this msg board is created to know that what is the view of small investors .and operators do oppssite. bu if you are smart enough then being a small investor you can also take benefit of what operators want.
they always increase stock price to sell their own shares and create panic to buy public holding at low.
hence always wait for panic selling and buy .....
now on ranbaxy you are certain to gain more than 100% if you remain invested for 24 months , but i have serious doubt that you have any holding in ranbaxy

what is the future of ranbaxy?

Posted by : Guest

what should i do in ranbaxy i bought 3000 share at 350.
hold or sell?

Accumulate Ranbaxy - victim of MNC Cartel

Posted by : WBuffetBlog

Smart investors will buy good stocks on bad news.

Its MNC cartel which is working over time in troubling Ranbaxy in regulated markets to stall its trail blazing growth with cheaper generics. This MNC cartel found Ranbaxy as a biggest threat for their existence whose drugs price are just crazily high priced.

Malvinder Singh's sell off of Ranbaxy to Japanese Dai-Ichi is an indication that Malvinder alone is not capable of taking on these MNC's so he joined the hands with bigger force Dai Ichi. Once Dai Ichi integration is completed, then Ranbaxy can look for better days under its new parent.

I am sure, Ranbaxy will come out of woods within few months now. The same USFDA will withdraw all charges against Ranbaxy & it will be business as usual.

A downward price below 250 can't be ruled out. And thats the time to lap up Ranbaxy for killing gains over long term.

Cheers!!!
WBuffetBlog

buy for target

Posted by : alwaysrocking

buy for a ST targrt of 300!!!

US likely to withdraw motion against Ranb

Posted by : steadyinvestor

US likely to withdraw motion against Ranbaxy ...

Normally I do not post copies of articles that are printed on other sites .. but this is too important to be ignored and therefore am reproducing this article ... for those who want to read it .. pls visit the online Economictimes dot com and then click on news by industry and then click on Healthcare section and then click on this article that is posted today.

I expect huge upside now and this time I hope the Sardarji really fixes the Ranbaxy problems and his credibility for good.

NEW DELHI: In what should bring some relief to Ranbaxy, the US Department of Justice (DoJ) may withdraw the motion against the company next week in a local court in the US.

The DoJ had filed the motion in the district court of Maryland in July to access data and documents which, it claimed, Ranbaxy and its legal consultancy firm Parexel were not disclosing. In its submission on Monday, DoJ said the legal consultancy firm hired by Ranbaxy has produced nearly five lakh documents so far and Ranbaxy intends to share the remaining documents which the US government has sought. “The government seeks an additional week to review the recent production (of documents) until October 6. Upon confirmation that the production is complete, the government will withdraw the motion,” the DoJ told the Maryland Court on Monday.

While the withdrawal of the motion may close legal proceedings against India’s largest drugmaker, it will not mean the end of Ranbaxy’s troubles in the US. The USFDA has recently banned imports of 30 drugs into the US, which are manufactured at the company’s two plants in India. The company and its executives are being investigated for document fraud and manufacturing sub-standard drugs. As if this was not enough, a US Congressional Committee has pulled up the FDA for being lax in investigating Ranbaxy. In addition, the US government has stopped sourcing three HIV drugs for its anti-AIDS drugs programme for Africa and other developing countries.


This series of setbacks has resulted in Ranbaxy’s shares tanking to Rs 251.70 at the Bombay Stock Exchange. On June 11, the company’s shares were trading at Rs 560. Incidentally, this was also the day that Daiichi Sankyo of Japan agreed to acquire the company at Rs 737 per share.

After the DoJ moved court on July 3, Ranbaxy agreed to share the documents, something that the company had earlier allegedly refused. The DoJ had said that it will withdraw the motion upon ‘full and complete production of Parexel documents’. The court gave the DoJ 60 days abeyance which ended on Wednesday.

“Since the motion to enforce was filed, counsel for Parexel has produced nearly 5,00,000 pages of electronic documents, including 1,50,000 electronic pages on September 26. For the past two months, counsel for the government and Parexel have conferred regularly about the production,” the DoJ said.

The US government has been unable to examine the 1,50,000 pages which were produced on Friday. Additionally, images of some papers are of poor quality, and in some instances, illegible. Both the company and the DoJ expects to resolve these issues soon. Ranbaxy has assured the government counsel that it intends to comply fully with the subpoena and the production to date has been substantial.

Accumulate Ranbaxy - victim of MNC Cartel

Posted by : Lalitdeshpandey

WBuffetBlog,

I expect 500 ODD points rally on Friday on the back of US bill passed. What do you think ?? Reliance and banking stocks may take the lead.

Accumulate Ranbaxy - victim of MNC Cartel

Posted by : psgs

hi WBB,
yes its a very good observation u have made. US is into recession, economy is getting bankrupt. people are losing jobs, earnings are coming down and cost of living is going up. drugs and medicines are part and parcel of their routine lives. so, they need cheaper drugs
in any case. so, they need Ranbaxy. its also a bear cartel playing against the counter. once the hammering is over. ranbaxy will recover sharply. the majority of the index fall from 15k to 12.5k is due to ranbaxy and other front line banks and real estate stocks....apart from few other stocks. so, i feel ranbaxy at current price is a steal buy for long term. but will there be an open offer/complete buyback/delisting if Dai ichi plans to do it? they may announce a buy back now as the stock is quoting at dam cheap levels.

swamy.

Accumulate Ranbaxy - victim of MNC Cartel

Posted by : WBuffetBlog

Smart investors will buy good stocks on bad news.

Its MNC cartel which is working over time in troubling Ranbaxy in regulated markets to stall its trail blazing growth with cheaper generics. This MNC cartel found Ranbaxy as a biggest threat for their existence whose drugs price are just crazily high priced.

Malvinder Singh's sell off of Ranbaxy to Japanese Dai-Ichi is an indication that Malvinder alone is not capable of taking on these MNC's so he joined the hands with bigger force Dai Ichi. Once Dai Ichi integration is completed, then Ranbaxy can look for better days under its new parent.

I am sure, Ranbaxy will come out of woods within few months now. The same USFDA will withdraw all charges against Ranbaxy & it will be business as usual.

A downward price below 250 can't be ruled out. And thats the time to lap up Ranbaxy for killing gains over long term.

Cheers!!!
WBuffetBlog

US likely to withdraw motion against Ranb

Posted by : steadyinvestor

US likely to withdraw motion against Ranbaxy ...

Normally I do not post copies of articles that are printed on other sites .. but this is too important to be ignored and therefore am reproducing this article ... for those who want to read it .. pls visit the online Economictimes dot com and then click on news by industry and then click on Healthcare section and then click on this article that is posted today.

I expect huge upside now and this time I hope the Sardarji really fixes the Ranbaxy problems and his credibility for good.

NEW DELHI: In what should bring some relief to Ranbaxy, the US Department of Justice (DoJ) may withdraw the motion against the company next week in a local court in the US.

The DoJ had filed the motion in the district court of Maryland in July to access data and documents which, it claimed, Ranbaxy and its legal consultancy firm Parexel were not disclosing. In its submission on Monday, DoJ said the legal consultancy firm hired by Ranbaxy has produced nearly five lakh documents so far and Ranbaxy intends to share the remaining documents which the US government has sought. “The government seeks an additional week to review the recent production (of documents) until October 6. Upon confirmation that the production is complete, the government will withdraw the motion,” the DoJ told the Maryland Court on Monday.

While the withdrawal of the motion may close legal proceedings against India’s largest drugmaker, it will not mean the end of Ranbaxy’s troubles in the US. The USFDA has recently banned imports of 30 drugs into the US, which are manufactured at the company’s two plants in India. The company and its executives are being investigated for document fraud and manufacturing sub-standard drugs. As if this was not enough, a US Congressional Committee has pulled up the FDA for being lax in investigating Ranbaxy. In addition, the US government has stopped sourcing three HIV drugs for its anti-AIDS drugs programme for Africa and other developing countries.


This series of setbacks has resulted in Ranbaxy’s shares tanking to Rs 251.70 at the Bombay Stock Exchange. On June 11, the company’s shares were trading at Rs 560. Incidentally, this was also the day that Daiichi Sankyo of Japan agreed to acquire the company at Rs 737 per share.

After the DoJ moved court on July 3, Ranbaxy agreed to share the documents, something that the company had earlier allegedly refused. The DoJ had said that it will withdraw the motion upon ‘full and complete production of Parexel documents’. The court gave the DoJ 60 days abeyance which ended on Wednesday.

“Since the motion to enforce was filed, counsel for Parexel has produced nearly 5,00,000 pages of electronic documents, including 1,50,000 electronic pages on September 26. For the past two months, counsel for the government and Parexel have conferred regularly about the production,” the DoJ said.

The US government has been unable to examine the 1,50,000 pages which were produced on Friday. Additionally, images of some papers are of poor quality, and in some instances, illegible. Both the company and the DoJ expects to resolve these issues soon. Ranbaxy has assured the government counsel that it intends to comply fully with the subpoena and the production to date has been substantial.